Weekly round up from Life Sciences Industry.
U.S. Representatives Peter Welch and Francis Rooney have sent a letter to the Federal Trade Commission and the Department of Justice urging a “careful examination” of Bristol-Myers Squibb’s $74B takeout of Celgene.
The lawmakers cite the potential negative impact on competition and drug prices as the reasons for their suggested scrutiny.
Date: January 21, 2019
Source: Investor Village
Send us an email, we will get in touch with you.
Sign up for DistilINFO e-Newsletters.
Amgen to buy Copenhagen-based Nuevolution for $167 million
Signaling Industry-Wide Shift to Integrated Mental Health, Quartet Announces Capital Raise and Strategic Partnership with Leading Medicaid Provider
Encoda Acquires Revenue Cycle Management Services Division from Microwize Technology
American Medical Technologies Announces Acquisition by One Equity Partners and The Silverfern Group
Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics
Apple Quietly Adds Updates to Noise App, Mobility Tracking
Picking Up the Pace: Healthcare’s Evolution to Social Media
OptimizeRx to Acquire Medicx Health for $95M